论文部分内容阅读
用诺卡氏菌与节杆菌混合菌种转化从蕃麻皂素制得的中间体5α-△~((?)(11))-16β-甲基-3β,17α,21三羟基孕甾烯-3β,21-双醋酸酯-20酮(Ⅰ)得50％的16β-甲基-△~(1,4,9(11))-孕甾三烯-20酮(Ⅱ)和少量的16β-甲基-9,11α环氧-△~1,4孕甾二烯-20酮(Ⅲ)。另外,又用同样的混合菌种转化从剑麻皂素制得的中间体5α,17α甲基-17β羟基-雄甾-3酮(Ⅳ)得50％17α甲基-17β羟基-△~(1,4)-雄甾二烯-3酮(Ⅴ)。如改变培养基则得3,17β-羟基-17α-甲基-9酮基-9,10开环-1,3,5(10)雄甾三烯化合物。
The intermediate 5α-△ ~ ((?) (11)) - 16β-methyl-3β, 17α, 21 trihydroxypregnanilide from Diphenralen was transformed with a mixed strain of Nocardia and Arthrobacter. 50% of 16β-methyl-Δ ~ (1,4,9 (11)) -pregnostan-20one (Ⅱ) and a small amount of 16β - methyl - 9,11α epoxy - △ ~ 1,4 pregnadiene - 20 ketone (Ⅲ). In addition, the same mixed bacterial strain was also used to transform the intermediate 5α, 17α methyl-17β hydroxy-androstan-3one (IV) obtained from tinderhine into 50% 17α methyl-17β hydroxy- 1,4) -androst-3-one (V). For example, changing the medium yields 3,17β-hydroxy-17α-methyl-9-keto-9,10 ring-1,3,5 (10) androstatrienyl compounds.